Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled trial of house dust mite sublingual tablets in Chinese participants with house dust mite allergic rhinitis/rhinoconjunctivitis
CTR20252606Phase 3Active
- Sponsor
- ALK-Abelló
- Start
- Nov 2025
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of House dust mite allergen extract in house dust mite allergic rhinitis, allergic rhinoconjunctivitis (ARC), sponsored by ALK-Abelló. Started Nov 2025; status: active.
02
Drugs
House dust mite allergen extract
03
Conditions
house dust mite allergic rhinitisallergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on CTR20252606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252606.